Therapeutic potential of amniotic fluid stem cells

Current Stem Cell Research and Therapy

Volumn 8, Issue 2, 2013, Pages 117-124

  Abdulrazzak, Hassan ^a   De Coppi, Paolo ^b   Guillot, Pascale V ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amniotic fluid; Amniotic fluid mesenchymal stem cells; Amniotic fluid stem cells; Cell therapy; Differentiation; Pluripotency; Tissue engineering

Indexed keywords

BIOLOGICAL MARKER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; POLYMER;

ADULT STEM CELL; AMNIOTIC FLUID CELL; AMNIOTIC FLUID STEM CELL; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; DNA MODIFICATION; EMBRYONIC STEM CELL; ENDODERM; EPIGENETICS; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESODERM; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

AMNIOTIC FLUID; CELL DIFFERENTIATION; HUMANS; IMMUNOMODULATION; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84875575864     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X11308020002     Document Type: Article

References (93)

1. Weissman I, Anderson D, Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol 2001; 17: 387-403.
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-7.
3. Andrews PW, Matin MM, Bahrami AR, et al. Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin. Biochem Soc Trans 2005; 33(Pt 6): 1526-30.
4. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev 2009; 30(3): 204-213.
5. Klimanskaya I, Chung Y, Becker S, et al. Derivation of human embryonic stem cells from single blastomeres. Nat Protoc 2007; 2(8): 1963-1972.
6. Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012; 379(9817): 713-720.
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
8. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
9. Maherali N, Sridharan R, Xie W, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 2007; 1(1): 55-70.
10. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 2011; 471(7336): 46-47.
11. Narsinh KH, Sun N, Sanchez-Freire V, et al. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. The Journal of clinical investigation 2011; 121(3): 1217-21.
12. Guillot PV, Gotherstrom C, Chan J, et al. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells 2007; 25(3): 646-654.
13. Rafei M, Hsieh J, Fortier S, et al. Mesenchymal stromal cellderived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 2008; 112(13): 4991-498.
14. Francois M, Galipeau J. New insights on translational development of mesenchymal stromal cells for suppressor therapy. J Cell Physiol 2012; 227(11): 3535-3538.
15. De Coppi P, Bartsch G, Jr., Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25(1): 100-106.
16. Moschidou D, Mukherjee S, Blundell MP, et al. Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach. Mol Ther 2012; 20(10): 1953-1967.
17. Abdulrazzak H, Moschidou D, Jones G, et al. Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface 2010; 7 Suppl 6; S689-S6706.
18. Ditadi A, de Coppi P, Picone O, et al. Human and murine amniotic fluid c-Kit+Lin- cells display hematopoietic activity. Blood 2009; 113(17): 3953-60.
19. Perin L, Giuliani S, Jin D, et al. Renal differentiation of amniotic fluid stem cells. Cell Prolif 2007; 40(6): 936-948.
20. Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: not just fetal urine anymore. J Perinatol 2005; 25(5): 341-348.
21. Miki T, Strom S. Amnion-derived pluripotent/multipotent stem cells. Stem Cell Rev 2006; 2(2): 133-1342.
22. Odibo AO, Gray DL, Dicke JM, et al. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16- year experience. Obstet Gynecol 2008; 111(3): 589-95.
23. Klemmt PA, Vafaizadeh V, Groner B. The potential of amniotic fluid stem cells for cellular therapy and tissue engineering. Expert Opin Biol Ther 2011; 11(10): 1297-12314.
24. Gosden CM. Amniotic fluid cell types and culture. Br Med Bull 1983; 39(4): 348-354.
25. Delo DM, De Coppi P, Bartsch G, Jr., et al. Amniotic fluid and placental stem cells. Methods Enzymol 2006; 419: 426-438.
26. Kunisaki SM, Armant M, Kao GS, et al. Tissue engineering from human mesenchymal amniocytes: a prelude to clinical trials. J Pediatr Surg 2007; 42(6): 974-979.
27. Cananzi M, Atala A, De Coppi P. Stem cells derived from amniotic fluid: new potentials in regenerative medicine. Reprod Biomed Online 2009; 18 Suppl 1: 17-27.
28. Gosden C, Brock DJ. Combined use of alphafetoprotein and amniotic fluid cell morphology in early prenatal diagnosis of fetal abnormalities. J Med Genet 1978; 15(4): 262-270.
29. Siegel N, Rosner M, Hanneder M, et al. Stem cells in amniotic fluid as new tools to study human genetic diseases. Stem Cell Rev 2007; 3(4): 256-264.
30. Torricelli F, Brizzi L, Bernabei PA, et al. Identification of hematopoietic progenitor cells in human amniotic fluid before the 12th week of gestation. Italian journal of anatomy and embryology 1993; 98(2): 119-126.
31. Streubel B, Martucci-Ivessa G, Fleck T, et al. [In vitro transformation of amniotic cells to muscle cells--background and outlook]. Wien Med Wochenschr 1996; 146(9-10): 216-217.
32. Ratajczak MZ, Zuba-Surma EK, Ratajczak J, et al. Very Small Embryonic Like (VSEL) Stem Cells - Characterization, Developmental Origin and Biological Significance. Exp Hematol 2008; 36(6): 742-751.
33. Da Sacco S, Sedrakyan S, Boldrin F, et al. Human amniotic fluid as a potential new source of organ specific precursor cells for future regenerative medicine applications. J Urol 2010; 183(3): 1193-1200.
34. Kaviani A, Perry TE, Dzakovic A, et al. The amniotic fluid as a source of cells for fetal tissue engineering. J Pediatr Surg 2001; 36(11): 1662-1665.
35. Tsai MS, Lee JL, Chang YJ, et al. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod 2004; 19(6): 1450-6.
36. Nadri S, Soleimani M. Comparative analysis of mesenchymal stromal cells from murine bone marrow and amniotic fluid. Cytotherapy 2007; 9(8): 729-737.
37. Tsai M-S, Hwang S-M, Chen K-D, et al. Functional network analysis of the transcriptomes of mesenchymal stem cells derived from amniotic fluid, amniotic membrane, cord blood, and bone marrow. Stem Cells 2007; 25(10): 2511-23.
38. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003; 102(4): 1548-9.
39. Roubelakis MG, Pappa KI, Bitsika V, et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007; 16(6): 931-52.
40. Sessarego N, Parodi A, Podestà M, et al. Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica 2008; 93(3): 339-346.
41. Prusa A-R, Marton E, Rosner M, et al. Oct-4-expressing cells in human amniotic fluid: a new source for stem cell research? Hum Reprod 2003; 18(7): 1489-1493.
42. Tsai M-S, Hwang S-M, Tsai Y-L, et al. Clonal amniotic fluidderived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 2006; 74(3): 545-551.
43. Chambers I, Silva J, Colby D, et al. Nanog safeguards pluripotency and mediates germline development. Nature 2007; 450(7173): 1230-124.
44. Kim J, Lee Y, Kim H, et al. Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif 2007; 40(1): 75-90.
45. McLaughlin D, Tsirimonaki E, Vallianatos G, et al. Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human amniotic fluid cells. J Neurosci Res 2006; 83(7): 1190-1200.
46. Jezierski A, Gruslin A, Tremblay R, et al. Probing stemness and neural commitment in human amniotic fluid cells. Stem Cell Rev 2010; 6(2): 199-214.
47. Bossolasco P, Montemurro T, Cova L, et al. Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Res 2006; 16(4): 329-336.
48. Toselli M, Cerbai E, Rossi F, et al. Do amniotic fluid-derived stem cells differentiate into neurons in vitro? Nat Biotechnol 2008; 26(3): 269-270.
49. Phermthai T, Odglun Y, Julavijitphong S, et al. A novel method to derive amniotic fluid stem cells for therapeutic purposes. BMC cell biology 2010; 11: 79.
50. Pan H, Yang D, Chiu Y, et al. Enhanced regeneration in injured sciatic nerve by human amniotic mesenchymal stem cell. J Clin Neurosci 2006; 13(5): 570-55.
51. Pan H, Cheng F, Chen C, et al. Post-injury regeneration in rat sciatic nerve facilitated by neurotrophic factors secreted by amniotic fluid mesenchymal stem cells. J Clin Neurosci 2007; 14(11): 1089-1098.
52. Cheng FC, Tai MH, Sheu ML, et al. Enhancement of regeneration with glia cell line-derived neurotrophic factor-transduced human amniotic fluid mesenchymal stem cells after sciatic nerve crush injury. J Neurosurg 2010; 112(4): 868-879.
53. Yang DY, Sheu ML, Su HL, et al. Dual regeneration of muscle and nerve by intravenous administration of human amniotic fluidderived mesenchymal stem cells regulated by stromal cell-derived factor-1alpha in a sciatic nerve injury model. J Neurosurg 2012; 116(6): 1357-1367.
54. Cipriani S, Bonini D, Marchina E, et al. Mesenchymal cells from human amniotic fluid survive and migrate after transplantation into adult rat brain. Cell Biol Int 2007; 31(8): 845-850.
55. Prasongchean W, Bagni M, Calzarossa C, et al. Amniotic fluid stem cells increase embryo survival following injury. Stem Cells Dev 2012; 21(5): 675-88.
56. Jezierski A, Rennie K, Tremblay R, et al. Human Amniotic Fluid Cells Form Functional Gap Junctions with Cortical Cells. Stem cells international 2012; 2012: 607161.
57. Galende E, Karakikes I, Edelmann L, et al. Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell Reprogram 2010; 12(2): 117-125.
58. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22(7): 1338-1345.
59. Saulnier N, Lattanzi W, Puglisi MA, et al. Mesenchymal stromal cells multipotency and plasticity: induction toward the hepatic lineage. European review for medical and pharmacological sciences 2009; 13 Suppl 1: 71-8.
60. Gekas J, Walther G, Skuk D, et al. In vitro and in vivo study of human amniotic fluid-derived stem cell differentiation into myogenic lineage. Clinical and experimental medicine 2010; 10(1): 1-6.
61. Guan X, Delo DM, Atala A, et al. In vitro cardiomyogenic potential of human amniotic fluid stem cells. J Tissue Eng Regen Med 2011; 5(3): 220-228.
62. Bollini S, Pozzobon M, Nobles M, et al. In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells. Stem Cell Rev 2011; 7(2): 364-80.
63. Kolambkar YM, Peister A, Soker S, et al. Chondrogenic differentiation of amniotic fluid-derived stem cells. J Mol Histol 2007; 38(5): 405-413.
64. Zhao P, Ise H, Hongo M, et al. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation 2005; 79(5): 528-535.
65. De Coppi P, Callegari A, Chiavegato A, et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol 2007; 177(1): 369-376.
66. Piccoli M, Franzin C, Bertin E, et al. Amniotic Fluid Stem Cells Restore the Muscle Cell Niche in a HSA-Cre, Smn(F7/F7) Mouse Model. Stem Cells 2012; 30(8): 1675-1684.
67. Perin L, Sedrakyan S, Giuliani S, et al. Protective effect of human amniotic fluid stem cells in an immunodeficient mouse model of acute tubular necrosis. PLoS One 2010; 5(2): e9357.
68. Rota C, Imberti B, Pozzobon M, et al. Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev 2012; 21(11): 1911-1923.
69. Langer R, Vacanti JP. Tissue engineering. Science 1993; 260(5110): 920-926.
70. Peister A, Deutsch ER, Kolambkar Y, et al. Amniotic fluid stem cells produce robust mineral deposits on biodegradable scaffolds. Tissue Eng Part A 2009; 15(10): 3129-38.
71. Rodrigues MT, Lee BK, Lee SJ, et al. The effect of differentiation stage of amniotic fluid stem cells on bone regeneration. Biomaterials 2012; 33(26): 6069-6078.
72. Steigman SA, Ahmed A, Shanti RM, et al. Sternal repair with bone grafts engineered from amniotic mesenchymal stem cells. J Pediatr Surg 2009; 44(6): 1120-1126
73. Turner CG, Klein JD, Gray FL, et al. Craniofacial repair with fetal bone grafts engineered from amniotic mesenchymal stem cells. J Surg Res 2012; 178(2): 785-790.
74. Fuchs JR, Kaviani A, Oh J-T, et al. Diaphragmatic reconstruction with autologous tendon engineered from mesenchymal amniocytes. J Pediatr Surg 2004; 39(6): 834-838.
75. Kunisaki SM, Fuchs JR, Kaviani A, et al. Diaphragmatic repair through fetal tissue engineering: a comparison between mesenchymal amniocyte- and myoblast-based constructs. J Pediatr Surg 2006; 41(1): 34-39.
76. Lee WY, Wei HJ, Lin WW, et al. Enhancement of cell retention and functional benefits in myocardial infarction using human amniotic-fluid stem-cell bodies enriched with endogenous ECM. Biomaterials 2011; 32(24): 5558-5567.
77. Yeh YC, Lee WY, Yu CL, et al. Cardiac repair with injectable cell sheet fragments of human amniotic fluid stem cells in an immunesuppressed rat model. Biomaterials 2010; 31(25): 6444-6453.
78. Schmidt D, Achermann J, Odermatt B, et al. Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation 2007; 116(11 Suppl): I64-I70.
79. Zheng YB, Gao ZL, Xie C, et al. Characterization and hepatogenic differentiation of mesenchymal stem cells from human amniotic fluid and human bone marrow: a comparative study. Cell Biol Int 2008; 32(11): 1439-1448.
80. Liu H, Liu DQ, Li BW, et al. Human amniotic fluid-derived stem cells can differentiate into hepatocyte-like cells in vitro and in vivo. In vitro Cell Dev Biol Anim 2011; 47(9): 601-8.
81. Li B, Wang S, Liu H, et al. Neuronal restrictive silencing factor silencing induces human amniotic fluid-derived stem cells differentiation into insulin-producing cells. Stem Cells Dev 2011; 20(7): 1223-1231.
82. Zagoura DS, Roubelakis MG, Bitsika V, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 2012; 61(6): 894-906.
83. Zheng YB, Zhang XH, Huang ZL, et al. Amniotic-fluid-derived mesenchymal stem cells overexpressing interleukin-1 receptor antagonist improve fulminant hepatic failure. PLoS One 2012; 7(7): e41392.
84. Carraro G, Perin L, Sedrakyan S, et al. Human amniotic fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 2008; 26(11): 2902-2911.
85. Gray FL, Turner CG, Ahmed A, et al. Prenatal tracheal reconstruction with a hybrid amniotic mesenchymal stem cellsengineered construct derived from decellularized airway. J Pediatr Surg 2012; 47(6): 1072-1079.
86. Santana AC, Dellê H, Cavaglieri RC, et al. Protective effects of human amniotic fluid stem cells in a model of aorta allograft vasculopathy in rats. Transplant Proc 2012; 44(8): 2490-2494.
87. Moorefield EC, McKee EE, Solchaga L, et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS 2011; 6(10): e26535.
88. Chiavegato A, Bollini S, Pozzobon M, et al. Human amniotic fluidderived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immunodeficient rat. J Mol Cell Cardiol 2007; 42(4): 746-759.
89. Gosemann JH, Kuebler JF, Pozzobon M, et al. Activation of regulatory T cells during inflammatory response is not an exclusive property of stem cells. PLoS One 2012; 7(4): e35512.
90. Wolfrum K, Wang Y, Prigione A, et al. The LARGE principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid-derived human iPS cells. PLoS One 2010; 5(10): e13703.
91. Li C, Zhou J, Shi G, et al. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum Mol Genet 2009; 18(22): 4340-4349.
92. Moschidou D, Mukherjee S, Blundell M, et al. Human midtrimester amniotic fluid stem cells cultured under embryonic stem cell conditions with Valproic acid acquire pluripotent characteristics. Stem Cells Dev 2013; 22(3): 444-458.
93. Atala A. Engineering organs. Curr Opin Biotechnol 2009; 20(5): 575-592.